At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 57 enrolled
Drug / intervention
TAK-925 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Patients With Narcolepsy
In Brief
A Phase 1 clinical trial evaluating TAK-925 and Placebo for Healthy Participants and Narcolepsy. Completed, enrolled 57 participants across 3 sites.
Detailed Summary
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925 when administered to healthy participants and narcolepsy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants, Narcolepsy
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartNov 2018
Primary CompletionOct 2019
TodayJul 2026
First PostedNov 21, 2018
Enrollment StartNov 21, 2018
Primary CompletionOct 24, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.6 years ago
Interventions
TAK-925drug
TAK-925
Placebodrug
TAK-925 Placebo